Navigation Links
Endo to Present at J.P. Morgan 28th Annual Healthcare Conference
Date:12/30/2009

CHADDS FORD, Pa., Dec. 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it will present at the J.P. Morgan 28th Annual Healthcare Conference on Wednesday, Jan. 13, 2010, at 10:00 a.m. PST. David Holveck, president and chief executive officer of Endo, will review the company's products and development programs.

The presentation will be webcast live and can be accessed from Endo's website at www.endo.com under the investors section.

About Endo

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP). Its products include LIDODERM®, a topical patch to relieve the pain of postherpetic neuralgia; Percocet® and Percodan® tablets for the relief of moderate-to-moderately severe pain; FROVA® tablets for the acute treatment of migraine attacks with or without aura in adults; OPANA® tablets for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate; OPANA® ER tablets for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time; Voltaren® Gel, which is owned and licensed by Novartis AG, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as those of the hands and the knees; VANTAS® for the palliative
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BD to Present at Investor Healthcare Conferences
2. Masimo to Present at the 28th Annual J.P. Morgan Healthcare Conference
3. Hospira to Present at J.P. Morgan 28th Annual Healthcare Conference Jan. 13, 2010
4. Jennerex Announces Presentations at Upcoming Conferences
5. Sigma-Aldrich to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
6. NewCardio to Sponsor and Present at 4th Annual Cardiac Safety Assessment Summit
7. The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting
8. Amnis to Present at the 28th Annual J.P. Morgan Healthcare Conference
9. Pitcher Joaquin Benoit, PADF Team Up to Send a Much-Needed Christmas Present to Haitis Hospitals
10. Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference
11. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... A new report by the Global Sanitation ... across 13 countries bring an end to open defecation. ... Progress Report details how its financial support for nationally-led ... communities become open-defecation free, improved toilets for 4.2 million ... hand-washing facilities. The Progress Report highlights cumulative ...
(Date:6/2/2015)... June 2, 2015 ... mejora  de 7,9 meses en la supervivencia libre ... con cáncer colorrectal metastático inoperable (mCRC) tratados  en ... Y-90 más quimioterapia    Los beneficios ... directamente al hígado con la quimioterapia sistémica actual ...
(Date:6/2/2015)... CHICAGO e MADRID , ... orale (abstract 10503) al meeting annuale della American Society ... i dati dello studio multicentrico di fase 3 SAR3007, ... Janssen , LLC (Janssen), hanno evidenziato un significativo miglioramento ... con trabectedina (YONDELIS ® ) rispetto al trattamento con ...
Breaking Medicine Technology:Global Sanitation Fund Reports Major Sanitation & Hygiene Advances for Seven Million People in 13 Countries 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 2Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 3Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 4Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 5Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 6Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 7Se presenta el estudio SIRFLOX en la reunión anual ASCO 2015 8PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 2PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 3PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 4PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 5PharmaMar annuncia che lo studio di Janssen ha evidenziato che la trabectedina migliora il controllo della malattia in pazienti con sarcoma dei tessuti molli in stato avanzato 6
... Loss, Lower Blood Sugar and Improved A1CHORSHAM, Pa., April 21 ... loss program that delivers to your door, today announced the ... specifically for the approximately 24 million Americans with diabetes, as ... for diabetes. In a clinical study at Temple ...
... clinical trial strategies for personalized approach to cancer ... a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) ... preclinical study, which utilized RNA interference (RNAi) and ... vulnerability" - that enhance the anti-tumor response to ...
Cached Medicine Technology:New Weight Loss Hope for People with Diabetes 2New Weight Loss Hope for People with Diabetes 3New Weight Loss Hope for People with Diabetes 4New Weight Loss Hope for People with Diabetes 5New Weight Loss Hope for People with Diabetes 6Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
(Date:6/2/2015)... 02, 2015 First Choice Emergency ... rooms in the United States, named Kenneth Alan Totz, ... Jones Road facility. , “We are pleased to ... Road facility,” said Dr. James M. Muzzarelli, Executive Medical ... Totz received his undergraduate degree from St. Edwards University ...
(Date:6/2/2015)... Amercanex, the American Cannabis Exchange, ... become Amercanex’s new Chief Technology Officer. Amercanex is ... cultivators, wholesale distributors and retail vendors can buy, ... transparent intra-state market. , Jim Miller is an ... space, helping innovative technology companies deliver on their ...
(Date:6/2/2015)... 02, 2015 FDA approved Orlistat for ... patients after a satisfactory doctor consultation. The less potent, over-the-counter ... several years and has the longest track record as an ... enzyme that breaks down fats in foods, Orlistat treatment prevents ... intestinal system to be excreted through feces. , ...
(Date:6/2/2015)... Vail, Colorado (PRWEB) June 02, 2015 ... and Chief Medical Officer at the Steadman Philippon Research ... It Too Early for Single Sport Specialization? ” This ... for Sports Medicine (AOSSM) Research Committee that was recently ... the data for this project was limited, there is ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Colleen’s Dream ... has granted $70,000 to the UNMC to support ovarian cancer ... Billy Cundiff, a member of the Colleen’s Dream Foundation Board ... was the biggest to date for Colleen’s Dream Foundation and ... in Omaha. , “Dr. Wang is a rising star in ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 2Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 3Health News:Diet Doc Adds FDA Approved Orlistat to their Medically Supervised Diet Plans, Offering Their Patients another Option for Trimming Fat from the Hard to Reach Areas 4Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 2Health News:Early Single Sport Specialization May Put Youth Athletes at Risk for Overuse Injuries According to Colorado Knee Specialist Robert LaPrade, MD, PhD 3Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 2Health News:Colleen’s Dream Foundation Grants $70,000 to the University of Nebraska Medical Center (UNMC) to Support Ovarian Cancer Research 3
... twins were conjoined from the breast bone to the ... pediatricians and nurses at Children,s Hospital of Pittsburgh of ... procedure.The 2-year-old twin girls -- Dagian and Danielle Lee, ... began at 6:30 a.m. Saturday, Dec. 13, 2008, and ...
... lead to more headaches, new study suggests , , MONDAY, Feb. ... by taking naps to sleep it off, but they run ... patterns and perpetuating the cycle of headaches, a new study ... things people tried to treat their headaches, and they rated ...
... a statement by American Heart Association President Timothy Gardner, ... provisions in the economic stimulus package are a win-win ... with increased financial burdens. Americans suffering from chronic ... -- see a doctor or pay for food and ...
... One of the nation,s first group of fertility ... cost reduction to patients challenged by economic downturnSAN ... a 25th-anniversary celebration, one of the nation,s first ... to couples and individuals struggling to find ways ...
... ARLINGTON, Texas, Feb. 16 Across the nation, countless ... executives at one North Texas healthcare company took some ... from being another victim to the economic crisis.2009 looks ... now in its 7th year. One year ago ten ...
... AlphaVax announced today that it has ... Regulatory, Quality and Clinical Operations. In this capacity ... the areas of regulatory and quality affairs and ... trials, developing regulatory strategy and gaining regulatory approval ...
Cached Medicine News:Health News:Conjoined Twins Separated by Surgical Team at Children's Hospital of Pittsburgh of UPMC During Complex, 24-Hour Procedure 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 2Health News:Using Sleep to Manage Headaches May Cause Insomnia 3Health News:Statement by American Heart Association President Timothy Gardner, M.D. on Congressional Approval of Economic Stimulus Package 2Health News:Bay Area Fertility Clinic to Offer Special Help During Recession 2Health News:Staying Healthy in 2009 2Health News:AlphaVax Announces New Vice President of Regulatory, Quality and Clinical Operations 2
... developed in surgeon's desire to have the ... instrument with the strength to maneuver into ... bending or breaking. Arthrotek Hand Instruments are ... the surgeon's hand. This new generation of ...
... Arthrotek® Precision Hand Instruments were developed in ... feel, while still having an instrument with ... without the fear of the bending or ... and manufactured to conform to the surgeon's ...
... Hand Instruments were developed in surgeon's desire ... still having an instrument with the strength ... fear of the bending or breaking. Arthrotek ... to conform to the surgeon's hand. This ...
... Instruments were developed in surgeon's desire to ... having an instrument with the strength to ... of the bending or breaking. Arthrotek Hand ... conform to the surgeon's hand. This new ...
Medicine Products: